Carisma Therapeutics Inc.
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
CARM | NDAQ
Overview
Corporate Details
- ISIN(s):
- US14216R1014 (+2 more)
- LEI:
- Country:
- United States of America
- Address:
- 3675 MARKET STREET, 19104 PHILADELPHIA
- Website:
- https://sesenbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering the development of engineered cell therapies. The company utilizes its proprietary macrophage and monocyte cell engineering platform to create first-in-class Chimeric Antigen Receptor Macrophage (CAR-M) therapeutics. These therapies are designed to leverage the unique abilities of macrophages to infiltrate solid tumors, directly kill cancer cells via targeted phagocytosis, and activate a broad anti-tumor immune response. Carisma is building a pipeline of programs focused on treating serious disorders, including solid tumors, fibrosis, and autoimmune diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Carisma Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Carisma Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Carisma Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
